Welcome to our dedicated page for Zura Bio news (Ticker: $ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zura Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zura Bio's position in the market.
Zura Bio reported financial results for Q1 2024, ending with $89.8M in cash and closing an oversubscribed $112.5M private placement in April. The company appointed a new CEO and CMO and is on track to start Phase 2 studies for SSc and HS. Cash runway extended through 2027. R&D expenses decreased, while G&A expenses increased. Net loss reduced. Anticipated milestones include Phase 2 trials for ZB-106 and monitoring of ZB-168 and ZB-880.